Ranbaxy Eyes Merck’s Generics Unit

Law360, New York (January 10, 2007, 12:00 AM EST) -- India’s Ranbaxy Laboratories Ltd. may become the latest big generic maker to jump on the buyout bandwagon, with the company revealing on Tuesday that it is interested in bidding for the generic drug unit of Germany’s Merck KGaA.

Malvinder Mohan Singh, Ranbaxy’s chief executive, told the Wall Street Journal that the company is looking to boost its position to become one of the top five generic makers worldwide, stating that Ranbaxy expects to be able to bid on the Merck unit by the end of January....
To view the full article, register now.